Five-year CARVYKTI data deepen evidence for durable remission in earlier-line multiple myeloma
CARVYKTI keeps half of CARTITUDE-2 patients progression-free and treatment-free at five years after one infusion. See what the data mean.
Pharma & Biotech
Medical Devices & Diagnostics
Johnson & Johnson targets earlier-line myeloma with CARVYKTI expansion
Johnson & Johnson’s CARVYKTI shows 80 percent treatment-free survival at 30 months in second-line myeloma. Is CAR-T moving to earlier use?